QUEBEC \u2013 Pancreatic cancer is one of the most lethal cancers,\nwith a survival rate of just 10% after five years. In 2024, it will claim over 6,100 lives in\nCanada and more than 500,000 worldwide. Unfortunately, current treatment options\nprovide limited clinical benefit with significant toxicity. Despite some recent research\nadvances, Meaningful and durable disease control remain unachieved; therefore, there\nis a critical need for new effective treatments.<\/p>\n\n
With this in mind, Neolys Pharma, a Quebec-based biotechnology startup, is pleased to\nannounce the progression of RM-581 as a promising new treatment for cancer patients.\nThis candidate drug, derived from our molecular platform, operates through a novel\nmechanism and primarily targets difficult-to-treat cancers, including pancreatic cancer,\nhormone-resistant prostate cancer, triple-negative breast cancer, small cell lung cancer,\nand colorectal cancer. Neolys Pharma recently secured seed funding of $1.1 million to\naccelerate the development of RM-581.<\/p>\n\n
This seed funding was made possible through private investors and a grant from the\nMinistry of Economy, Innovation, and Energy (MEIE) under the \u201cPSO\u201d program, which\nwas awarded to the CHU de Qu\u00e9bec \u2013 Universit\u00e9 Laval Research Center (CRCHUQ-UL)\nand the Faculty of Medicine at Laval University. Support from Axelys in business\ncoaching, technological maturation, and intellectual property protection has also\ncontributed to this success.<\/p>\n\n
\u201cPancreatic cancer remains one of the most challenging cancers, primarily due to late\ndiagnosis and limited treatment options. Our goal is to develop RM-581 as an effective\nyet well-tolerated alternative for patients. This molecule is administered orally and has\nshown excellent tolerance in animal models, which contrasts with traditional\nchemotherapy agents. RM-581 has also demonstrated its ability to combine effectively\nwith other anticancer agents. We anticipate that human clinical trials will begin in the\nnext two to three years,\u201d<\/i>\n– Christian Roby, CEO of Neolys Pharma.<\/p>\n\n
\u201dWe are very proud to have supported Neolys Pharma through several important stages\nof their development. We celebrate this news for Christian Roby and his outstanding team,\nas it positions this Quebec startup to evolve into a global player in the biopharmaceutical\nsector. With Neolys Pharma, we have the potential to offer a truly significant innovation\nthat can reshape healthcare for all Quebecers. This is a new example of what Axelys can\nachieve in turning public research ideas into innovations,”<\/i><\/p>\n\n
<\/i>\u00ab This is a new example of what Axelys can\nachieve in turning public research ideas into innovations,”<\/i> – Jesse Vincent-Herscovici, CEO\nof Axelys.<\/p>\n\n
Founded in 2023 by Christian Roby, researchers Donald Poirier and Ren\u00e9 Maltais, the\nfounding team of Neolys Pharma includes Dr. Poirier\u2019s team at CRCHUQ-UL, who\nembarked twenty years ago on a research program that led to the discovery of a new\nfamily of broad-spectrum anticancer agents, of which RM-581 is a very promising\ncandidate. Encouraging results have been obtained on cancers with poor prognosis. In\nmouse cancer model of pancreatic cancer, RM-581 demonstrated its ability to shrink\ntumors to an undetectable level after just one month of treatment.<\/p>\n\n
Neolys Pharma has signed an exclusive global license option for the development and\ncommercialization of RM-581, an innovative molecule patented by Laval University. Over\nthe months, the co-founders have attracted a team of seasoned experts and\ncollaborators motivated by the hope of improving the prognosis for pancreatic cancer\npatients and raising its low survival rate.<\/p>\n\n
Neolys Pharma extends its gratitude to all stakeholders who have made this crucial step\npossible toward developing an innovative therapy that could transform the lives of many\npatients.<\/p>\n\n
Mitacs\u2019 Elevation program also contributes to the success of RM-581\u2019s development\nthrough a co-funded postdoctoral scholarship with NEOLYS PHARMA, allowing this\nvaluable resource to continue this work while providing a professional development\nprogram for the intern.<\/p>\n\n
The company also plans to raise additional funds in the coming months to support its\nresearch and development towards clinical trials.<\/p>\n\n
Neolys Pharma (www.neolyspharma.ca<\/a>) is a Quebec-based biopharmaceutical company\ndedicated to developing innovative therapies for various types of cancer, with a\nparticular focus on hard-to-treat cancers. Our mission is to give a second chance to\npatients with hard-to-treat cancers through innovative treatments.<\/p>\n\n The largest French-speaking research center in North America, the CHU de Qu\u00e9bec \u2013\nUniversit\u00e9 Laval Research Center includes 1,092 researchers, 1,531 staff members, and\n1,215 graduate students across five sites in Quebec. With its exceptional research teams\nand state-of-the-art facilities, the organization enjoys an enviable national and\ninternational reputation. www.crchudequebec.ulaval.ca<\/a><\/p>\n\n Axelys is Quebec\u2019s public research innovation development and transfer company. It\ncontributes to the province’s economic and social prosperity by accelerating the\nmaturation and deployment of high-potential inventions, know-how, or processes into\ninnovations that can improve the world in which we live. It also supports scientific\ncompanies emerging from public research, such as Neolys Pharma.<\/p>\n\n Christian Roby \n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":true},"categories":[],"class_list":["post-680","nouvelles","type-nouvelles","status-publish","hentry"],"acf":[],"yoast_head":"\nABOUT CHU DE QUEBEC \u2013 UNIVERSIT\u00c9 LAVAL RESEARCH CENTER<\/h4><\/p>\n\n
ABOUT AXELYS<\/h4><\/p>\n\n
MEDIA CONTACTS<\/h4><\/p>\n\n
\nPresident and CEO
\nNeolys Pharma
\nWebsite : www.neolyspharma.ca<\/a>
\nEmail: christian.roby@neolyspharma.ca<\/a>
\nPhone: +1.418-931-2195<\/a>